指南与共识消化道肿瘤放疗姑息放疗与转移瘤

前瞻性放疗质量保证推动复发性直肠癌靶区勾画指南优化:PelvEx II 研究经验

Prospective radiotherapy quality Assurance leads to delineation guideline refinements for recurrent rectal cancer: Experience from the PelvEx II study.
指南 / 共识 · Clin Transl Radiat Oncol · 2025-02-13

PelvEx II 研究对 113 例局部复发性直肠癌患者在放化疗前进行前瞻性靶区勾画质量保证(QA),QA 依从率为 90%,48% 病例靶区发生改变,再照射患者 GTV 中位增加 29%(p < 0.001)、CTV 中位增加 15%(p < 0.001),未放疗患者 CTV 中位增加 6%(p = 0.002),最终形成 13 项方案修订。

要点

  • 113 例局部复发性直肠癌前瞻性 QA 依从率 90%,53% 病例完全遵循全部指南推荐。
  • QA 后 48% 病例靶区改变,再照射患者 GTV 中位 +29%、CTV 中位 +15%(均 p < 0.001)。
  • 未放疗患者 QA 后 CTV 中位 +6%(p = 0.002),共形成 13 项方案修订。

核心结论

  • 局部复发性直肠癌靶区同行评审可使高达 48% 的病例靶区发生改变,并促成勾画指南更新。

研究设计与样本

  • PelvEx II 试验中所有接受放化疗的局部复发性直肠癌患者(未放疗者 50-50.4 Gy,再照射者 30 Gy)在治疗前接受前瞻性 QA。
  • 每例患者治疗前由治疗医师与 QA 团队在线会议同行评审勾画,对 7 项(再照射)或 8 项(未放疗)指南推荐逐项评分。

主要发现

  • 共前瞻性评审 113 例局部复发性直肠癌,QA 依从率 90%,53% 病例遵循全部指南推荐。
  • 建议改变 GTV 者 21 例、改变 CTV 者 39 例。
  • 再照射患者 QA 后 GTV 中位增加 29%(p < 0.001)、CTV 中位增加 15%(p < 0.001)。
  • 未放疗患者 QA 后 CTV 中位增加 6%(p = 0.002)。
  • 30 例(27%)偏离方案被接受,共商定 13 项方案修订。

关键数值与推荐

  • 未放疗患者放疗剂量 50-50.4 Gy,再照射患者剂量 30 Gy。
  • 指南推荐依从性按 7 项(再照射)或 8 项(未放疗)逐项评分。

临床怎么用

  • 局部复发性直肠癌放化疗前应开展前瞻性靶区同行评审 QA,以识别靶区调整需求并推动指南完善。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Target volume delineation in locally recurrent rectal cancer (LRRC) is clinically challenging. To ensure the quality of chemoradiotherapy (CRT) within the PelvEx II trial, a delineation guideline was developed and prospective quality assurance (QA) was instated for all patients. Guideline adherence, the impact of QA on target volumes, and subsequent guideline refinements are described in this paper. METHODS AND MATERIALS: All PelvEx II patients, either RT naive patients (50-50.4 Gy) or reirradiation (30 Gy) patients, were eligible for QA prior to CRT. An online meeting with the treating physician and the QA team was planned for each patient prior to treatment, to peer review delineations. Adherence to each of the 7 (reirradiation) or 8 (RT naive) guideline recommendations was scored. Suggested target volume adjustments and any reasons to deviate from protocol were noted. When applicable, target volumes before and after QA were compared. Possible protocol refinements were discussed amongst the trial QA team. RESULTS: Prospective review of 113 cases of LRRC was performed, resulting in a high QA compliance rate of 90 %. All guideline recommendations were followed in 53 % of cases. Changes to the GTV and CTV were advised in 21 and 39 cases respectively. A median increase of GTV (+29 % (p < 0.001)) and CTV (+15 % (p < 0.001)) was seen in reirradiation patients, versus a median CTV increase of + 6 % (p = 0.002) in RT naive patients following QA. Deviations from protocol were accepted in 30 cases (27 %). Thirteen protocol refinements were agreed upon. CONCLUSION: Peer-review of LRRC target volumes leads to altered target volumes in up to 48% of cases, resulting in an updated delineation guideline.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Piqeur F, Hupkens BJP, Creemers DMJ, et al. Prospective radiotherapy quality Assurance leads to delineation guideline refinements for recurrent rectal cancer: Experience from the PelvEx II study. Clin Transl Radiat Oncol. 2025. PMID: 40071235. doi:10.1016/j.ctro.2025.100934

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。